VANCOMYCIN THERAPEUTIC DRUG-MONITORING - IS IT NECESSARY

被引:0
作者
FREEMAN, CD
QUINTILIANI, R
NIGHTINGALE, CH
机构
[1] HARTFORD HOSP, DEPT RES, ERC BLDG, 80 SEYMOUR ST, HARTFORD, CT 06115 USA
[2] HARTFORD HOSP, DIV INFECT DIS ALLERGY IMMUNOL, HARTFORD, CT 06115 USA
[3] UNIV CONNECTICUT, SCH MED, DEPT MED, HARTFORD, CT 06112 USA
[4] UNIV CONNECTICUT, SCH PHARM, HARTFORD, CT 06112 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the literature and assess the validity of obtaining vancomycin serum drug concentrations in patients. DATA SOURCES: A MEDLINE search of the English literature and a bibliographic review of articles pertaining to vancomycin serum concentrations, their use, and the rationale of cited therapeutic ranges. STUDY SELECTION AND DATA EXTRACTION: Studies pertaining to the use of vancomycin concentrations in the clinical setting, methods for predicting these concentrations, and studies that reported efficacy or toxicity associated with vancomycin use and possible correlation of serum concentrations. DATA SYNTHESIS: The usefulness of vancomycin serum concentrations, the determination of a therapeutic range of values, and their correlation to antibacterial efficacy and drug toxicity in the clinical setting are controversial. Old reports of toxicities need to be critically examined due to lack of information and the actual frequency of toxic reactions. The efficacy of vancomycin's antibacterial effect and its correlation with reported therapeutic ranges may advocate obtaining a vancomycin trough concentration in certain groups of patients. CONCLUSIONS: Determination of serum vancomycin concentrations in the clinical setting and their usefulness in patient care is questionable and unnecessary in the majority of patients.
引用
收藏
页码:594 / 598
页数:5
相关论文
共 41 条
[1]   ANALYSIS OF VANCOMYCIN TIME-KILL STUDIES WITH STAPHYLOCOCCUS SPECIES BY USING A CURVE STRIPPING PROGRAM TO DESCRIBE THE RELATIONSHIP BETWEEN CONCENTRATION AND PHARMACODYNAMIC RESPONSE [J].
ACKERMAN, BH ;
VANNIER, AM ;
EUDY, EB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1766-1769
[2]   VANCOMYCIN PHARMACOKINETICS IN NORMAL AND MORBIDLY OBESE SUBJECTS [J].
BLOUIN, RA ;
BAUER, LA ;
MILLER, DD ;
RECORD, KE ;
GRIFFEN, WO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (04) :575-580
[3]  
BRUMMETT RE, 1990, ARCH OTOLARYNGOL, V116, P61
[4]   RELATIONSHIP OF SERUM ANTIBIOTIC CONCENTRATIONS TO NEPHROTOXICITY IN CANCER-PATIENTS RECEIVING CONCURRENT AMINOGLYCOSIDE AND VANCOMYCIN THERAPY [J].
CIMINO, MA ;
ROTSTEIN, C ;
SLAUGHTER, RL ;
EMRICH, LJ .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (06) :1091-1097
[5]  
EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652
[6]   RETROSPECTIVE STUDY OF THE TOXICITY OF PREPARATIONS OF VANCOMYCIN FROM 1974 TO 1981 [J].
FARBER, BF ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (01) :138-141
[7]   SURVEY OF VANCOMYCIN MONITORING GUIDELINES IN ILLINOIS HOSPITALS [J].
FITZSIMMONS, WE ;
POSTELNICK, MJ ;
TORTORICE, PV .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (7-8) :598-600
[8]  
GABRIEL MH, 1991, CLIN PHARMACY, V10, P129
[9]  
GARRELTS JC, 1987, CLIN PHARMACY, V6, P795
[10]   ALTERED VANCOMYCIN DOSE VS SERUM CONCENTRATION RELATIONSHIP IN BURN PATIENTS [J].
GARRELTS, JC ;
PETERIE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :9-13